Effect of Empagliflozin on Heart Failure–Related Events in Symptomatic Patients
NEJM Journal Watch（2021）
摘要
The industry-funded EMPEROR-Preserved trial (NCT03057951) demonstrated a significant benefit of the sodium–glucose cotransporter-2 inhibitor (SGLT-2i)
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要